Smith & Nephew plc vs ProShares UltraPro S&P500 — how do they compare? Smith & Nephew plc trades at $27.67 (market cap $11.63B), while ProShares UltraPro S&P500 trades at $148.04. The key difference: Smith & Nephew plc pays a 2.85% dividend while ProShares UltraPro S&P500 pays none, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| SNN | UPRO | |
|---|---|---|
Market Cap | $11.63B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $38.53 | $157.66 |
52-Week Low | $27.80 | $89.29 |
Enterprise Value | $14.66B | — |
Dividend Yield | 2.85% | — |
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
UPRO trades at $149.32, down 1.69% with neutral technical signals. The stock shows mixed technical indicators with bullish moving averages but neutral oscillators. Recent S&P 500 market discussions highlight AI-driven growth potential alongside concerns about high valuations and geopolitical risks. The stock faces support at $146 and resistance at $151, with overall market sentiment balanced between optimism and caution.
The outlook for UPRO remains tied to broader S&P 500 performance, with potential upside from AI productivity gains but risks from elevated valuations and interest rate uncertainty. Investors face a balanced risk-reward profile with technical support providing near-term stability.
Trailing returns across standard periods
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →